Last reviewed · How we verify

Levemir (insulin detemir)

Rabin Medical Center · FDA-approved active Small molecule

Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.

Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameLevemir (insulin detemir)
SponsorRabin Medical Center
Drug classLong-acting basal insulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin detemir is a modified human insulin analog with a fatty acid chain attached, which allows it to bind reversibly to albumin in the bloodstream, creating a depot effect that extends its duration of action to approximately 24 hours. It mimics the body's basal insulin secretion by activating insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and glycogen synthesis while inhibiting gluconeogenesis and lipolysis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: